| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2011: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2009: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Research Abstract |
We have revealed that CD133-positive cells in oral squamous cell carcinoma cells has an important role for the sphere formation and side population cells also function for tumorigenicity and drug-resistance activity. In addition, epidermal growth factor, sonic hedgehog, interleukin-6 derived from the OSCC work as niche for the maintenance and property of CD133 cells. These results strongly suggested the possibility that CD133 and/ or Sp cells function as a cancer stem cell in oral squamous cell carcinomas. Thus, targeted therapy against the CD133 and/ or Sp cell might be useful for the OSCC therapy
|
